|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
PhytoMedical Technologies, Inc. (PYTO.OB) Partners with Renowned Specialty Laboratory Latitude Pharmaceuticals Inc. to Develop an IV Formulation for Its Successfully Tested Anti-Cancer Compound for Glioblastoma
8/5/2009 9:02:42 AM
PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced their partnership with LATITUDE Pharmaceuticals, Inc. to develop an IV Formulation for its lead anti cancer compound for glioblastoma. LATITUDE Pharmaceuticals, Inc. is a widely recognized expert in the area of drug formulations and delivery systems. “Given LATITUDE’s successful track record in formulation development, we are extremely pleased to have partnered with such an innovative group of experts,” commented PhytoMedical, President, CEO, Greg Wujek. “The development and subsequent testing of the IV Formulation are key components in PhytoMedical’s quest to provide physicians and their patients with an effective treatment option for this most difficult to treat and often deadly form of brain cancer.”
|
|
|
|
|
|
|
|
|
|
|